Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00517101|
Recruitment Status : Unknown
Verified August 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : August 16, 2007
Last Update Posted : August 16, 2007
A relationship between IBD and spondyloarthropathy is well recognized. ASCA ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for Crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. More recently, new serological markers for IBD have been described. These markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of IBD.
The aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.
|Condition or disease|
|Psoriatic Arthritis Ankylosing Spondylitis Undifferentiated Spondyloarthropathy|
|Study Type :||Observational|
|Observational Model:||Defined Population|
|Study Start Date :||September 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00517101
|Principal Investigator:||valerie aloush, MD||Tel-Aviv Sourasky Medical Center|